Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene by Buffa, F M et al.
Large meta-analysis of multiple cancers reveals a common,
compact and highly prognostic hypoxia metagene
FM Buffa*,1, AL Harris
1, CM West
2 and CJ Miller
3
1Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK;
2School of Cancer and Imaging Sciences, The University of
Manchester, Manchester, M13 9PT, UK;
3Paterson Institute for Cancer Research, The University of Manchester, Manchester, M20 4BX, UK
BACKGROUND: There is a need to develop robust and clinically applicable gene expression signatures. Hypoxia is a key factor
promoting solid tumour progression and resistance to therapy; a hypoxia signature has the potential to be not only prognostic but
also to predict benefit from particular interventions.
METHODS: An approach for deriving signatures that combine knowledge of gene function and analysis of in vivo co-expression patterns
was used to define a common hypoxia signature from three head and neck and five breast cancer studies. Previously validated
hypoxia-regulated genes (seeds) were used to generate hypoxia co-expression cancer networks.
RESULTS: A common hypoxia signature, or metagene, was derived by selecting genes that were consistently co-expressed with the
hypoxia seeds in multiple cancers. This was highly enriched for hypoxia-regulated pathways, and prognostic in multivariate analyses.
Genes with the highest connectivity were also the most prognostic, and a reduced metagene consisting of a small number of top-
ranked genes, including VEGFA, SLC2A1 and PGAM1, outperformed both a larger signature and reported signatures in independent
data sets of head and neck, breast and lung cancers.
CONCLUSION: Combined knowledge of multiple genes’ function from in vitro experiments together with meta-analysis of multiple
cancers can deliver compact and robust signatures suitable for clinical application.
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Gene-expression studies attempt to extrapolate biologically and
clinically relevant hypotheses from gene expression patterns.
However, many current studies make little use of existing
knowledge such as gene function within specific pathways, and
prognostic signatures are often derived with no reference to the
functional roles of their components.
One increasingly popular method that aims to make use of prior
knowledge is gene set enrichment analysis (GSEA) (Subramanian
et al, 2005). It first conducts a supervised analysis by ranking
genes according to their ability to discriminate between different
sample groups, and then maps them onto previously defined
gene sets, typically formed according to common function using
annotation sources. The goal is to identify sets containing a
statistically significant number of highly ranked genes, and then
to use this information to provide functional characterisations
for the samples in question. Although powerful, GSEA relies on
stratification of the experimental samples into distinct groups,
often making it unsuitable for use with heterogeneous clinical
data sets.
Another approach often applied to microarray data involves
creation of a co-expression network within which each ‘node’ repre-
sents a gene, and ‘edges’ are created between genes when their expres-
sion patterns are significantly correlated. Co-expression networks have
been used to formulate functional and clinical hypotheses from in vivo
data (Butte and Kohane, 2003; Hahn and Kern, 2005; Wolfe et al,
2005). A disadvantage with the approach is that it can be susceptible to
the multiple testing issues that arise due to the large number of genes
represented on a typical microarray. Setting a low threshold for a
significant correlation between genes will result in the inclusion of
many spurious links, whereas a high threshold will control the false-
positive rate at the expense of omitting many genuine edges.
Here we illustrate and validate a network-based approach with
parallels to both GSEA and co-expression networks; for a workflow
of the method see Supplementary Material and Methods. It can be
applied directly to clinical data, even when the samples cannot be
partitioned in advance into distinct groups. The algorithm begins
with a collection of ‘seed’ genes that are then used as starting point
from which to build an association network. Rather than simply
connect gene pairs with high correlation between their expression
profiles, the approach defines a ‘neighbourhood of co-expression’
around each seed gene, and then connects seeds that have a
significant degree of overlap between their neighbourhoods. This
approach is relatively robust against the inclusion of spurious
edges, as edges are only added when there is consistently high
correlation to many intermediate genes that form the intersection
between seeds. We previously used a seed-based approach
successfully to predict hypoxia-related genes (Winter et al,
2007); this study develops the method in a meta-analysis context
to produce robust signatures requiring fewer genes, making them
more suitable for clinical use, for example in quantitative RT-PCR
analyses of biopsies at presentation. Received 8 September 2009; accepted 14 October 2009
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cancers including head and neck squamous cell carcinomas
(HNSCCs) (Nordsmark et al, 2005) and breast carcinomas (BCs)
(Fox et al, 2007); thus the identification of common hypoxia-
regulated genes is important both for understanding of cancer
evolution, and for improved prognosis or development of novel
therapies. The described approach was applied to a large meta-
analysis of HNSCCs and BCs to define successfully a common and
robust hypoxia signature.
MATERIALS AND METHODS
Seed clustering
The process begins with k seed genes,
Q
¼{p1,p1,ypk} (‘gene’ is
used throughout for convenience, although ‘transcript’ is generally
more accurate). Spearman’s correlation, r, is computed between
seeds and genes Y¼{y1, y2,yym} in a data set of n samples,
X¼{x1, x2,yxn}. For each seed/gene pair, their ‘affinity’ is defined
as:
dðpi; yjÞ¼ 1 þ e
ðWt r2
pi;yj
Þ
Ws
"#  1
ð1Þ
where yt and ys define extent and sharpness of the cluster.
When ys -0, d reduces to the step function with d ¼0
if r
2oyt, d¼1i fr
24yt. In this limit, the method is parameter
free, and this will be used in this study. yt is defined objectively
using a probability threshold, a, of observing a given correla-
tion if the null hypothesis (i.e. no association) was true.
This needs to be corrected for multiple testing (Hastie
et al, 2001) to account for the size of Y; here, a¼0.05 after
Bonferroni correction was considered. Finally, a membership
function is defined:
gðyi; pkÞ¼dðyi; pkÞ=
X K
j¼1
dðyi; pjÞð 2Þ
An increasing g indicates stronger membership of a gene to a
seed cluster.
Shared neighbourhood
The shared neighbourhood, S, between two seeds is defined as:
Sðpi; pjÞ¼
P m
k¼1;k6¼i;j
min½gðpi; ykÞ; gðpj; ykÞ 
P m
k¼1;k6¼i;j
max½gðpi; ykÞ; gðpj; ykÞ 
ð3Þ
where g is the membership (Eq. 2). Two seeds are considered
to carry a high degree of related information if their clusters
share many genes (high S values). A sign function is also
defined:
Fðpi; pjÞ¼
P m
k¼1;k6¼i;j
min½gðpi; ykÞ; gðpj; ykÞ :sgn½rðpi; ykÞrðpj; ykÞ 
P m
k¼1;k6¼i;j
min½gðpi; ykÞ; gðpj; ykÞ 
ð4Þ
where sgn(x) is the sign function: sgn(x)¼1i fx40, sgn(x)¼ 1i f
xo0. If two seeds are correlated with their shared features in
the same direction, F¼1 (seeds are fully concordant); if they are
correlated with their shared features in opposite direction, F¼ 1.
Seed-dependent connectivity
The strength of the relationship between a gene and the whole set
of seeds is estimated using the connectivity function:
CðyiÞ¼
P K
j¼1;j6¼i
wðpjÞgðyi; pjÞ
P K
h¼1;h6¼i
wðphÞ
ð5Þ
where g is defined in Eq. 2 and w are weights that regulate the
importance of each seed. In this study, we consider w¼1, unless yi
is one of the seeds, or a probe set biding to the same transcript as
the seed; in this case, to avoid bias, w¼0 for that seed.
A connectivity score is defined as the fractional rank of C; that is
the ranking normalised between 0 (lowest C) and 1 (highest C).
Bootstrapping, Monte Carlo and meta-connectivity score
Random sets of seeds are generated by Monte Carlo sampling,
clusters are aggregated around them, and C and S are calculated.
This procedure is repeated to generate null distributions and it
provides an estimate of the probability of observing by chance a
given value of C and S.
Bootstrapping is re-sampling with replacement of the original
population; it is used to provide maximum likelihood best
estimates when an analytical approach is not feasible (Hastie
et al, 2001). Here, it is used to provide best estimates and
confidence limits for C and S. These are used in a meta-analysis
across several data sets to define a meta-connectivity score as:
^ CðyiÞ¼
P Nd
h¼1
R½CðyiÞ h=s2
h
P Nd
h¼1
1=s2
h
ð6Þ
where R[C(yi)]k is the fractional rank of C (Eq. 5), Nd is the number
of datasets, s
2
k is the variance of the ranked C,R [ C(yi)]k, in dataset
k for gene yi.
A common metagene between tumour types is derived by taking
the C ˆ scores product, pC ˆ. This is effectively a rank product, as C ˆ is
an average rank (Eq. 6).
Cumulative forest plots based on connectivity score
A summary expression score, E, is defined in each sample as the
median of the absolute expression of the genes in the signature.
The median is used as summary statistics to reduce the effect of
outliers. A cumulative forest plot is defined: genes are added to the
signature, one by one, in order of their connectivity, C, score so
that genes that are introduced first have the highest connectivity.
At each step, a summary expression, E, is derived using the new
gene and genes from the previous steps. Samples are then ranked
by their E value; this assigns a hypoxia score (HS) from lowest
(least hypoxic) to highest (most hypoxic). Hypoxia score is then
re-normalised between 0 and 1; introduced into a Cox multivariate
analysis that includes the other significant clinical covariates and
the hazard ratio (HR) of the HS is calculated.
Data sets, data processing and annotation
NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) was searched for gene expression studies in cancer,
published in peer-reviewed journals, where microarray were
performed on frozen material extracted before chemotherapy,
radiotherapy or adjuvant treatment. Eight data sets (Table 1)
were selected that used similar platforms (Affymetrix U133A, B
and plus2, www.affymetrix.com). Processing was performed using
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to estimate expression values, data were quantile-normalised and
logged (base2). Other data sets were identified for validation in
which different technologies were used (Table 1); non-Affymetrix
data sets were processed as described in the original publications.
More details on pre-processing and annotation are given in the
Supplementary Methods.
RESULTS
Derivation of a hypoxia expression network
A hypoxia expression network was built first in a data set
comprising 59 HNSCC tumour samples (Vice 125; Table 1) using
well-characterised hypoxia-related genes identified from the
literature covering a comprehensive set of hypoxia-induced
pathways (set A, Supplementary Table S1). These were adreno-
medullin (ADM), adenylate kinase 3-like 1 (AK3L1), BCL2/
adenovirus E1B 19kDa interacting protein 3 (BNIP3), carbonic
anhydrase IX (CA9), enolase 1 (ENO1), hexokinase 2 (HK2), lactate
dehydrogenase A (LDHA), phosphoglycerate kinase 1 (PGK1),
solute carrier family 2 member 1 (SLC2A1) and solute carrier
family 2 (VEGFA). The resultant network (Figure 1) was observed
to map distinct regions of the Reactome (www.reactome.org)
network and several hypoxia-related pathways (Figures 2; Supple-
mentary Figure S1). The method was applied to additional HNSCC
and BC training data sets (Table 1) with similar results
(Supplementary Table S2).
In the resulting expression networks, high shared neighbour-
hood, S (Eq. 3), values between seed pairs were generally
associated with a high pair-wise correlation. However, this
relationship did not always hold. An example is given in
Supplementary Figure S2, where genes in a published 245-gene
literature list (LL) (Winter et al, 2007) were used as starting seeds.
Many of the seeds with high pair-wise S but low correlation
appeared in the same KEGG (http://www.genome.jp/kegg/) path-
way but could not be detected in a straightforward correlation
analysis (Supplementary Figure S2). Furthermore some seeds
showed markedly different in vivo and in vitro behaviours; for
example, PFKFB3 (set B, Supplementary Table S1) did not have
significant overlap with any other seeds, whereas CCNG2 showed a
consistent inverse correlation with other seeds (Fo0; Eq. 4),
supporting results from previous studies (Choi and Chen, 2005).
Thus, the method was able to identify seeds that behave differently
from their peers; for the rest of this study, only the conservative
seed set A was used. This set showed higher pair-wise S values than
any other set of randomly selected seeds (repeated 1000 times)
from the 245-gene LL.
Seed-dependent connectivity identifies a hypoxia signature
Genes in the co-expression networks were ranked by their
connectivity score, C (Eq. 5), and compared with the hypoxia
245-gene LL. As the latter is biased towards up-regulated genes
(Harris, 2002), only genes showing consistent positive correlation
with the initial seeds were considered. To avoid bias, the initial
seeds were excluded from this comparison. The relative proportion
of known hypoxia genes increased with increasing connectivity, C,
score (Figure 2), confirming its benefit as a metric for predicting
functional relationships. Similar results were observed with different
clustering and pre-processing methods (Supplementary Figure S3).
However, differences were observed between data sets. Much of
this inter-experimental variation is likely to reflect differences in
both the patient populations and the processing of the biological
material. For example, both data sets GSE6791 and GSE3494, which
showed a lower level of enrichment for hypoxia genes than others,
featured samples with the highest proportions of tumour cells
selected either by microdissection or visual scoring.
Next we selected a subset of ‘hub’ genes from the hypoxia
network, with the goal of using them as a hypoxia signature. Genes
with high connectivity, C (Eq. 5), score (Po0.01, estimated by
Monte Carlo simulation) were considered (Supplementary Table
S2). Each of these genes had a greater-than-expected overlap with
the neighbourhoods of all other genes in the hypoxia network
(Supplementary Figure S4). The seeds were only selected if they
were hubs with respect to all other seeds. Using the Reactome
database, we confirmed that pathways known to be regulated by
hypoxia, such as glycolysis, gluconeogenesis, glucose metabolism
and Cori cycle (recycling of lactic acid), were consistently over-
represented in these genes (Figure 2; Supplementary Table S3).
Similarly, GO analysis (http://genecodis.dacya.ucm.es) found over-
representation (false discovery rate o0.05) of pathways such as
glycolysis, phosphoinositide-mediated signalling, nuclear mRNA
splicing, translational initiation, regulation of cell cycle, ubiquitin-
dependent protein catabolism, apoptosis and regulation of cell
proliferation. Over-represented molecular functions included ATP
binding, nucleotide binding, lipoic acid binding, oxidoreductase
and L-lactate dehydrogenase activity.
Meta-signature enrichment and the prognostic value of
compact signatures
We selected genes that showed consistent high connectivity across
data sets and derived meta-signatures for hypoxia in HNSCC and
BC. Interestingly, although some of the data sets performed poorly
on their own, meta-analysis signatures were robust to their
inclusion and performed well (Figures 2B and C).
We assessed the prognostic relevance of meta-signatures in
four independent data sets (Table 1). Samples were ranked using
a summary expression score, E, of the genes in the signature;
this produced a hypoxia score, which assigns a hypoxic status
to the tumours in the validation data sets. Multivariate Cox
analysis including available clinical factors was carried out using
each data set; clinical variables were selected using backward-
stepwise maximum likelihood. The HS was introduced into the
reduced clinical model to estimate the prognostic significance of
the meta-signatures independently from other clinical variables
(Supplementary Figure S5 and Table S4).
To address whether smaller signatures with equal prognostic
ability could be derived by using a more stringent C score,
cumulative forest plots were generated in which genes were
introduced into the HS calculation one by one, in decreasing order
of their meta-C ˆ score (Supplementary Figure S5). Only a few genes
were needed before the HR stabilised and a reduced signature was
found to be at least as prognostic as a larger one (Supplementary
Figure S5 and Table S4). Interestingly, when genes were introduced
into the cumulative plots in random order, rather than by their
Table 1 Data sets used to train and validate the hypoxia signature
Name Size Site Reference
Training data sets
Vice125 59 HN Winter et al (2007)
GSE2379 20 HN Cromer et al (2004)
GSE6791 42 HN Pyeon et al (2007)
GSE6532Oxf 149 Breast Loi et al (2008)
GSE6532KI 178 Breast Loi et al (2008)
GSE6532GUY 87 Breast Loi et al (2008)
GSE2034 286 Breast Carroll et al (2006)
GSE3494 315 Breast Miller et al (2005)
Validation data sets
NKI 295 Breast van de Vijver et al (2002)
Beer 86 Lung Beer et al (2002)
GSE4573 130 Lung Raponi et al (2006)
Chung 60 HN Chung et al (2004)
Abbreviation: HN¼head and neck.
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prognostic significance (Supplementary Figure S5).
A common hypoxia metagene across cancer types
Common hubs in HNSCC and BC were selected by considering, for
each gene, the product, pC ˆ, of the C ˆ scores between the HNSCC
and BC meta-analyses. A common metagene was derived by
considering genes with pC ˆ40.5 (Table 2; Supplementary Table
S5). This hard cut-off was chosen because a gene with a pC ˆ score
approaching that which would be expected by chance (pC ˆE0.5) in
one tumour site would have to achieve a maximal score in the
other tumour site to be included.
We investigated in cell lines potential regulation of genes in the
common metagene by hypoxia and by HIF1a, the main mediator
of the hypoxia response in cancer. We considered two data sets:
a hypoxia time course in a panel of epithelial and endothelial
non-malignant cells (Chi et al, 2006), and an HIF1a and HIF2a
siRNA experiment in MCF7 BC cells (Elvidge et al, 2006) exposed to
hypoxia. For details of these data we refer to the original publications.
Although differences between cell lines and BC in vivo are expected,
a high proportion of genes in the common metagene (38 out of 51)
showed either regulation in the hypoxia time course or in the siRNA
experiment (Figure 3A, B; Supplementary Table S5). Several of these
genes were also predicted as HIF1a targets and showed potential
HIF1a binding sites (Supplementary Table S5). Furthermore, 22 had
already been found hypoxia regulated by previously published report
(Supplementary Table S5). Overall approximately 80% (42 out of 51)
of genes in the common metagene were confirmed by at least one
validation, several of them by more than one.
The common hypoxia metagene was prognostic in independent
data sets of different cancer types (Table 3) and showed greater
prognostic power than (1) an in vitro derived hypoxia signature
(Chi et al, 2006), (2) the initial seeds and (3) our 99-gene
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Figure 1 Hypoxia gene-expression network in HNSCC (Vice 125 data set). Seeds (yellow) and learnt genes (blue) are shown; circle size is proportional
to C score. Genes with top 20% C scores are shown. Solid edges connect cluster members with seeds; length is proportional to membership, colour
represents Spearman correlation (blue,  1; red, þ1). Green dotted edges connect seeds; their length is proportional to the shared neighbourhood, S.
This figure appears in colour in the HTML version.
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A signature derived by selecting genes co-expressed with VEGF in
BC (Desmedt et al, 2008) had no independent prognostic
significance (data not shown), in agreement with the published
study. In a further validation using Oncomine (http://www.
oncomine.org), all but one of the 15 top-ranked (by pC ˆ score)
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Figure 2 Hypoxia network mapped onto Reactome pathways (A) coloured by increasing C score from dark blue to bright red; and validation of
up-regulated HNSCC (B) and BC (C) signatures by comparison with the literature. The proportion of literature-validated genes is shown as function
of the number of top-ranked (by C score) genes considered; standard errors estimated by bootstrap. This figure appears in colour in the HTML version.
Table 2 Top-ranked genes of the common hypoxia metagene
HGNC
symbol Names Pathway (source)
Breast ranked
score
HNSCC ranked
score
Common score
(
Q
C ˆ )
VEGFA Vascular endothelial
growth factor A
VEGF signalling (KEGG) 0.99 0.99 0.98
SLC2A1 Solute carrier family 2, member 1 Adipocytokine signalling (KEGG) 0.99 0.98 0.97
PGAM1 Phosphoglycerate mutase 1 Glycolysis/Gluconeogenesis (KEGG) 0.96 1.00 0.96
ENO1 Enolase 1 Glycolysis/Gluconeogenesis (KEGG) 0.97 0.98 0.95
LDHA Lactate dehydrogenase A Glycolysis/Gluconeogenesis (KEGG) 0.94 1.00 0.93
TPI1 Triosephosphate isomerase 1 Glycolysis/Gluconeogenesis (KEGG) 0.92 0.99 0.91
P4HA1 Prolyl 4-hydroxylase,
a-polypeptide I
Arginine and proline metabolism (KEGG) 0.83 1.00 0.83
MRPS17 Mitochondrial ribosomal
protein S17
Transport (GO:0006810) 0.84 0.97 0.82
CDKN3 Cyclin-dependent kinase
inhibitor 3
G1/S transition of mitotic cell cycle
(GO:0000082)
0.85 0.95 0.81
ADM Adrenomedullin Signal transduction (GO:0007165) 0.74 1.00 0.74
NDRG1 N-myc downstream regulated 1 Response to metal ion (GO:0010038) 0.71 0.99 0.71
TUBB6 Tubulin, b6 Gap junction (KEGG) 0.85 0.84 0.71
ALDOA Aldolase A, fructose-bisphosphate Glycolysis/Gluconeogenesis (KEGG) 0.86 0.80 0.69
MIF Macrophage migration inhibitory
factor
Tyrosine metabolism (KEGG) 0.71 0.93 0.66
ACOT7 Acyl-CoA thioesterase 7 Lipid metabolism (KEGG) 0.73 0.89 0.65
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(Po0.0001). The only top gene for which prognostic significance
was not reported in Oncomine, SLC2A1 (GLUT1), is prognostic in
other studies (Oliver et al, 2004).
Finally, cumulative forest plots based on connectivity score
(Figure 3) showed no further improvement in HR after addition of a
small number of genes. Although differences were observed between
HNSCC, BC and lung cancers, we found in all cases that a common
signature reduced to a small number of pC ˆ score top-ranked genes
w a sa tl e a s ta sp r o g n o s t i ca st h ef u l ls i g n a t u r e( F i g u r e3 C ,D ;T a b l e3 ) .
DISCUSSION
Hypoxia is a frequent feature of poor-prognosis tumours, and the
identification of common in vivo hypoxia-related genes is desirable
both for prognostic stratification of patients and development of
novel therapies. Although prognostic markers of hypoxia have been
identified, there are discrepancies between studies and powerful
methods used in large meta-analyses are needed to define generally
applicable signatures. A method is described for defining a hypoxia
signature that combines previous knowledge derived from in vitro
experiments, with co-expression data produced from in vivo
samples. We show that by constructing a gene expression network
and then extracting core ‘hub’ (high connectivity) genes it is possible
to define signatures that are significantly enriched for phenotype-
specific genes, and pathways. Although we have used this method
to derive a compact and clinically relevant signature of hypoxia in
cancer, the approach is likely to have broader applicability.
Specifically, we used the described method in a meta-analysis
of 1136 HNSCCs and BCs to derive tissue-specific and common
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Figure 3 Common hypoxia signature of 51 genes. (A) Hypoxia/normoxia expression ratio in endothelial, smooth muscle, human mammalian epithelial,
renal proximal tubule epithelial cells (EC, SMC, HMEC, RPTEC); and in (B) HIF1a/HIF2a siRNA experiment. (C, D) Connectivity-ranked forest plots:
metastases- and recurrence-free survival (MFS, RFS) hazard ratio (HR) (red) with 95% confidence intervals, and HRs if permuted list (black). Control: random
sampling of N¼51 genes ( 100 resampling).
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useful across multiple experiments or tissue types. The ability of
the method to derive highly prognostic hypoxia signatures despite
differences between data sets highlights its robustness.
The gene expression network used to construct the signature
was found to be biologically relevant and to map to a discrete set of
biochemical pathways, which is significantly enriched for hypoxia-
regulated genes and pathways. This finding highlights that not only
in vitro data can assist understanding of clinical data, but also the
reverse, that clinical data can be used to formulate specific
biological hypotheses.
Remarkably, a reduced common hypoxia metagene containing
as few as three genes, namely VEGFA, SLC2A1 and PGAM1, was as
prognostic as a large signature in independent BC and HNSCC
series. Furthermore, it was more prognostic than several reported
signatures when tested in a set of independent data sets, suggesting
a level of general applicability. Specifically, genes with highest
connectivity were also the most prognostic across a panel of
cancers. This further validates the method, as prognosis was not
used to select genes that were only ranked by their connectivity;
and this ranking was derived in independent data sets. Although
a reduced signature was prognostic in all tumour sites tested,
the number of genes before convergence was lower in HNSCC
and BC than lung cancer. This offers another positive control
as this was a common signature between HNSCC and BC, thus
it is expected to reflect their biology to a better extent; however,
it also indicates a degree of tumour specificity. The common
signature and the tumour-type-specific signatures are being
evaluated in prospective prognostic and predictive studies in
HNSCC and breast cancer.
In summary, this study uses information from in vitro
experiments regarding the function of multiple genes combined
with in vivo co-expression patterns to derive a common hypoxia
metagene in multiple cancers that is highly prognostic, while being
compact and robust.
ACKNOWLEDGEMENTS
This work was supported by Cancer Research UK, the EU
Integrated Project ACGT (FP6-IST-026996) and 7th Framework
Programme METOXIA, the Oxford NIHR Comprehensive Biome-
dical Research Centre, the Manchester Experimental Cancer
Medicine Centre and the Medical Research Council, UK. We
thank Carla Moller for useful comments on the paper. Special
thanks to all the authors of the studies summarised in Table 1.
Conflict of interest
FM Buffa, CJ Miller, CM West and AL Harris are applicants on a
patent submission seeking to use a reduced hypoxia signature as a
prognostic marker in cancer.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
B e e rD G ,K a r d i aS L ,H u a n gC C ,G i o r d a n oT J ,L e v i nA M ,M i s e kD E ,L i nL ,C h e n
G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM,
Iannettoni MD, Orringer MB, Hanash S (2002) Gene-expression profiles
predict survival of patients with lung adenocarcinoma. Nat Med 8: 816–824
Butte AJ, Kohane IS (2003) Relevance networks: a first step towards finding
genetic regulatory networks within microarray data. In The Analysis of
Gene Expression Data Parmigiani G, Gar-rett ES, Irizarry RA, Zeger S
(eds). Springer-Verlag: New York
Table 3 Prognostic significance of the common hypoxia metagene versus other hypoxia signatures
Data
(Table 1)
End point and
significant clinical
covariates (Cov.)
a
In vitro hypoxia
signature
(Chi et al, 2006)
HN hypoxia
metagene
(Winter et al, 2007)
Initial
seeds
b
PCA
score
c
CHM
51genes
Reduced
CHM
d
k genes
NKI End point: MFS
Cov.: Age, tumour size, nodal
status, grade, adj. treatment
2.94
(1.39, 6.23)
P¼0.005
3.58
(1.53, 8.39)
P¼0.003
2.41
(1.05, 5.53)
P¼0.038
3.22
(1.37, 7.56)
P¼0.007
4.15
(1.73, 9.96)
P¼0.002
5.58
(2.41, 12.90)
Po0.001, k¼3
GSE2034
e End point: RFS
Cov.: NA
2.20
(1.11, 4.34)
P¼0.024
1.92
(0.97, 3.78)
P¼0.061
2.36
(0.95, 3.77)
P¼0.014
1.98
(1.01, 3.90)
P¼0.048
3.22
(1.63, 6.35)
P¼0.001
4.15
(2.10, 8.18)
Po0.001, k¼10
GSE3494
e End point: DSS
Cov.: ER, PgR, tumour size,
nodal status
1.19
(0.45, 3.13)
P¼0.732
2.07
(0.77, 5.53)
P¼0.149
2.87
(1.25, 4.49)
P¼0.029
3.61
(1.33, 9.82)
P¼0.012
3.16
(1.05, 9.53)
P¼0.042
4.27
(1.53, 11.94)
P¼0.006, k¼2
Chung End point: RFS
Cov.: Intrinsic sign.,
differentiation, batch (strata)
3.06
(0.53, 17.6)
P¼0.210
14.83
(1.8, 122.4)
P¼0.012
6.71
(0.93, 48.4)
P¼0.059
1.25
(0.14, 11.4)
P¼0.840
6.25
(0.83, 47.2)
P¼0.077
34.66
(4.26, 281.95)
P¼0.001, k¼2
Beer End point: OS
Cov.: Stage
2.59
(1.59, 4.2)
P¼0.829
6.90
(1.34, 35.6)
P¼0.021
3.98
(0.72, 22.0)
P¼0.114
3.45
(0.59, 20.0)
P¼0.168
12.84
(1.71, 96.5)
P¼0.014
24.57
(2.83, 213.36)
P¼0.004, k¼23
GSE4573 End point: OS
Cov.: Nodal status
3.15
(1.32, 7.54)
P¼0.010
1.49
(0.65, 3.43)
P¼0.350
2.31
(0.93, 5.72)
P¼0.070
1.61
(1.14, 2.3)
P¼0.035
2.75
(1.15, 6.56)
P¼0.023
2.90
(1.27, 6.61)
P¼0.012, k¼38
Abbreviations: CHM¼common hypoxia metagene; DSS¼disease-specific survival; ER/PgR¼estrogen/progesterone receptor; MFS¼metastases-free survival; RFS¼recur-
rence-free survival; OS¼overall survival.
aReduced models of clinical covariates are derived using backward-stepwise likelihood. Signature scores are entered into the
reduced model; hazard ratio, 95% confidence limits and significance (model with and without the signature) are shown.
bSummary score, E, is calculated for the signature
including only the initial seeds.
cScore obtained using principal components analysis (Supplementary Methods).
dAt convergence in the cumulative forest plots.
eThese two
data sets were used to develop the signature but no training on outcome was carried out.
A common and compact prognostic hypoxia metagene
FM Buffa et al
434
British Journal of Cancer (2010) 102(2), 428–435 & 2010 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sCarroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS,
Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V,
Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M (2006) Genome-wide
analysis of estrogen receptor binding sites. Nat Genet 38: 1289–1297
Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y,
Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT,
Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006) Gene expression
programs in response to hypoxia: cell type specificity and prognostic
significance in human cancers. PLoS Med 3: e47
Choi P, Chen C (2005) Genetic expression profiles and biologic pathway
alterations in head and neck squamous cell carcinoma. Cancer 104:
1113–1128
Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D,
Butterfoss D, Xiang D, Zanation A, Yin X, Shockley WW, Weissler MC,
Dressler LG, Shores CG, Yarbrough WG, Perou CM (2004) Molecular
classification of head and neck squamous cell carcinomas using patterns
of gene expression. Cancer Cell 5: 489–500
Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, Lemaire F, Young J,
Dembe ´le ´ D, Thibault C, Muller D, Poch O, Abecassis J, Wasylyk B (2004)
Identification of genes associated with tumorigenesis and metastatic
potential of hypopharyngeal cancer by microarray analysis. Oncogene 23:
2484–2498
Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi
G, Delorenzi M, Piccart M, Sotiriou C (2008) Biological processes
associated with breast cancer clinical outcome depend on the molecular
subtypes. Clin Cancer Res 14: 5158–5165
Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM
(2006) Concordant regulation of gene expression by hypoxia and 2-
oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha,
HIF-2alpha, and other pathways. J Biol Chem 281: 15215–15226
Fox SB, Generali DG, Harris AL (2007) Breast tumour angiogenesis. Breast
Cancer Res 9: 216
Hahn MW, Kern AD (2005) Comparative genomics of centrality and
essentiality in three eukaryotic protein-interaction networks. Mol Biol
Evol 22: 803–806
Harris AL (2002) Hypoxia—a key regulatory factor in tumour growth. Nat
Rev Cancer 2: 38–47
Hastie R, Tibshirani J, Friedman H (2001) The Elements of Statistical
Learning: Data Mining, Inference, and Prediction. Springer-Verlag:
New York
Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet
C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen
MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C (2008)
Predicting prognosis using molecular profiling in estrogen receptor-
positive breast cancer treated with tamoxifen. BMC Genomics 9: 239
Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall
P, Klaar S, Liu ET, Bergh J (2005) An expression signature for p53 status
in human breast cancer predicts mutation status, transcriptional effects,
and patient survival. Proc Natl Acad Sci USA 102: 13550–13555
Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker
A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J (2005) Prognostic
value of tumor oxygenation in 397 head and neck tumors after primary
radiation therapy. An international multi-center study. Radiother Oncol
77: 18–24
Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ, Airley RE
(2004) Prognostic value of facilitative glucose transporter Glut-1 in
oral squamous cell carcinomas treated by surgical resection; results
of EORTC Translational Research Fund studies. Eur J Cancer 40:
503–507
Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, Marsit CJ,
Woodworth CD, Connor JP, Haugen TH, Smith EM, Kelsey KT, Turek
LP, Ahlquist P (2007) Fundamental differences in cell cycle deregulation
in human papillomavirus-positive and human papillomavirus-negative
head/neck and cervical cancers. Cancer Res 67: 4605–4619
Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, Macdonald J, Thomas
D, Moskaluk C, Wang Y, Beer DG (2006) Gene expression signatures for
predicting prognosis of squamous cell and adenocarcinomas of the lung.
Cancer Res 66: 7466–7472
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette
MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005)
Gene set enrichment analysis: a knowledge-based approach for inter-
preting genome-wide expression profiles. Proc Natl Acad Sci USA 102:
15545–15550
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW,
Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D,
Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H,
Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-
expression signature as a predictor of survival in breast cancer. N Engl J
Med 347: 1999–2009
Wilson CL, Miller CJ (2005) Simpleaffy: a BioConductor package for
Affymetrix Quality Control and data analysis. Bioinformatics 21:
3683–3685
Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, Shah KA,
Cox GJ, Corbridge RJ, Homer JJ, Musgrove B, Slevin N, Sloan P, Price P,
West CM, Harris AL (2007) Relation of a hypoxia metagene derived from
head and neck cancer to prognosis of multiple cancers. Cancer Res 67:
3441–3449
Wolfe CJ, Kohane IS, Butte AJ (2005) Systematic survey reveals general
applicability of ‘guilt-by-association’ within gene coexpression networks.
BMC Bioinformatics 6: 227
A common and compact prognostic hypoxia metagene
FM Buffa et al
435
British Journal of Cancer (2010) 102(2), 428–435 & 2010 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s